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Explainable recommendations and calibrated trust – 
Research protocol 
Calibrated trust has become an important design goal when designing Human-AI 
collaborative decision-making tools. It refers to a successful understandability, reliability 
and predictability to the AI-based tool behaviour and recommendations. Explainable AI 
is an emerging field where explanations accompany AI-based recommendations to help 
the human-decision maker understand, rely on, and predict AI behaviour. Such an 
approach is supposed to improve humans’ trust calibration while working collaboratively 
with an AI. However, evidence from the literature suggests that explanations have not 
contributed to improved trust calibration and even introduced other errors. Designers of 
such explainable systems often assumed that humans would engage cognitively with AI-
based explanations and use them in their Human-AI collaborative decision-making task. 
This research explores users’ behaviour and interaction style with AI-based explanations 
during a Human-AI collaborative decision-making task. Such an investigation will help 
further studies address design solutions for AI explanations to enhance trust calibration 
and operationalize explainability during a Human-AI decision-making task. To achieve 
this goal, we conduct a multi-stage qualitative study. It includes think-aloud protocol, 
follow-up interviews and observations. The results of these studies will guide the research 
to develop an understanding of the main research question in the literature: “Why 
explanations do not improve trust calibration?”. It will also help our future research to 
devise a design method for the XAI interface to enhance trust calibration. In the following 
subsection, we explained the procedures and provided the supplementary materials used 
in each study. The study workflow is summarised in Figure 1. 
Demographics and 
profile questions












Figure 1 Study workflow for each participant 
Phase 1: think-aloud protocol – first stage.  
We aim to provide explanatory information that supports the medical practitioners in their 
trust calibration during Human-AI collaborative decision-making task.  Our participant's 
inclusion criteria were based on their experience of using clinical decision support 
systems in their settings and experience in screening chemotherapy prescription (See 
Appendix A). We designed ten recommendations accompanied by ten different 
explanations. The adopted recommendations were generated to be non-trivial, which was 
based on a literature review on related work and medical expert judgment. We tested the 
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material and activities with two participants and refined them to optimise their fulfilment 
of these criteria (See Appendix B). Also, we validated the material with a medical 
oncologist with a focus on the border cases that need an investigation from the 
participants in the actual study. This ultimately helped put our participants, who were 
medical experts, in a realistic setting: exposing them to an imperfect AI-based 
recommendation and its explanations where trust calibration is needed and where errors 
in that process are possible. We consulted with one AI expert and one medical expert, 
presenting them with ten explainable interfaces, and asked them for their expert opinion 
regarding the relevance of the explanations and the validity of the recommendation. We 
used these opinions, as well as the results from our pilot study, to refine the interface 
design. Each scenario considered a hypothetical patient profile and AI-recommendations 
that suggests either rejecting or accepting a chemotherapy prescription for the patient. 
Patients have been initialised with fictional names and profiles to make it more realistic 
to our practitioners. Each scenario was accompanied by one different explanation class 
and was meant to be either correct recommendation or incorrect recommendation. We 
used our five main explanation classes revealed from our previous literature review (See 
Appendix C). We encouraged them to think aloud during their decision-making process. 
Then, they were asked to think freely and encouraged to make optimal decisions. 


































Fig 2. Five explanation classes mock-up interface presented to our participants. (a) confidence 
explanation. (b) Example-based explanation (c) Local feature importance (d) Counterfactual 
explanation (e) Global feature importance. 
Phase 2. Post-interview questions. 
At this stage, follow-up interviews were used to clarify the collected observations and 
participants think-aloud data and gather insights from the participants about their lived 
experience with AI explanations. This helped us to understand the nature of the users’ 
errors and confirm our observations. The following questions summarises the questions 
asked to the participants. 
 
General questions.  
1. How would you summarise why the AI-supported decision tool made the 
recommendations? 
2. What did you think of this explanation?  
3. Can you explain the results of the AI recommendation in your own words? 
4. How do you think the explanation could help you in your everyday decision-making 
activity?  
Questions regarding a specific action during the think-aloud protocol. 
 
1. Can you tell us why did you do that ….?  
2. What did you think about that scenario? 
3. What would you do in that scenario if you were in your clinic?  
 
 
Appendix A. Scenarios characteristics 
  
 
• Please provide your age category.  
▪ 20-30  
▪ 30-40  
▪ 40-50  
▪ 50-60  
• Please provide your gender.  
▪ Male  
▪ Female  
  
• Approximately how long have you been practicing clinically?  
▪ 0-5  
▪ 5-10  
▪ 10-15  
▪ 15-20  
▪ More than 20  
  
• Please check all statements that apply regarding your level of experience screening 
chemotherapy prescriptions.  
▪ I know what screening prescription.   
▪ I have used a clinical decision support software.  
  
Please indicate your level of agreement with the following statements.   
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  Strongly 
Disagree  
Disagree  Neutral  Agree  Agree 
Strongly  
Artificial Intelligence will play an 
important role in the future of medicine   
  
          
There are too many complexities and 
barriers in medicine for AI to help in 
clinical settings.  
  
          
I have reservations about using AI in 
clinical settings.  
  




Appendix B. Scenarios characteristics 
 
Scenario Number Explanation class Type of recommendation 
SC1 Confidence  Correct 
SC2 Confidence  Incorrect 
SC3 Counterfactual Correct 
SC4 Counterfactual Incorrect 
SC5 Global  Correct 
SC6 Global  Incorrect 
SC7 Local  Correct 
SC8 Local  Incorrect  
SC9 Example-based  Correct 
SC10 Example-based  Incorrect 













Male: 44  
not CHF 
ER Positive Positive Positive Negative 
No prior treatment 
with CDK 4/6 
Yes Yes Yes Yes 
Adequate renal and 
hepatic function 
Yes Yes Yes  Yes 
ECOG PS 2 0 1 2 
Neutrophils 1.20 0.9 1.00 0.7 
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Plt  80 74 33 84 
Hepatic 
impairment 
A B A C 
Other Toxicities Grade 1 Grate 2 Grade 1 Grade 4 
Table 2 Four examples of four patients’ profiles presented in the scenarios. 
 




















Ranking the data 
features. 
 
(Lou et al., 2013, Nguyen et al., 2016, 
Tolomei et al., 2017) 
 
Dependencies between 
data features  
 











(Bastani et al., 2017, Johansson and Niklasson, 2009, Krishnan et 
al., 1999, Bastani et al., 2017, Johansson and Niklasson, 2009, 









(Dash et al., 2018, Aung et al., 2007, 
Wei et al., 2019, Tan et al., 2018, Zhou 












(Ribeiro et al., 2016b, Lundberg and Lee, 2017, Simonyan et al., 
2013, Fong and Vedaldi, 2017, Dabkowski and Gal, 2017, Zhou et 
al., 2003, Mishra et al., 2017, Ribeiro et al., 2016a) 
Local rules and 
trees 
(Guidotti et al., 2018a, Krishnan and Wu, 2017) (Ribeiro et al., 







Prototype (Bien and Tibshirani, 2011, Kim et al., 2016) (Kim et al., 2014) 
(Kim et al., 2016, Kanehira and Harada, 2019) 
Counterfactual 
example 
(Wachter et al., 2017) (Martens and Provost, 2014, Chen et al., 
2017) (Laugel et al., 2017, Mothilal et al., 2020) 
Influential 
example 
(Koh and Liang, 2017) (Goodfellow et al., 2014) (Yuan et al., 







(Woodward, 1997) (Apley, 2016, Friedman, 2001, Goldstein et 
al., 2015) (Krause et al., 2016) 
Counterfactual 
features 
(Wachter et al., 2017) (Dhurandhar et al., 2018, Wachter et al., 




Confidence  (Zhang et al., 2020, Bussone et al., 2015)  (Gal and Ghahramani, 2016, Schulam and 
Saria, 2019) (Josse et al., 2019, Graves, 2011, Blundell et al., 2015) (Srivastava et al., 
2014) (Hooker, 2004) (Hendrycks and Gimpel, 2016). 
 
 
